Category: Glucose monitor
Researchers at the Mass. Institute of Technology are developing a lap-top-size machine that reads blood-glucose levels with near-infrared light, without requiring a finger-prick blood sample.
Mass. Institute of Technology researchers are working on technology that could make pinprick blood tests obsolete for Type I diabetes patients.
MIT Spectroscopy Laboratory graduate students Ishan Barman and Chae-Ryon Kong are developing a system that shines near-infrared light through about a half-millimeter of skin and uses body chemistry and Raman spectroscopy to measure the amount of glucose in the blood stream.
A Draper Laboratory scientist develops an implantable nanosensor to analyze blood glucose levels without pin-pricks.
In Iron Man 2, our hero Tony Stark manages to save the world from the military-industrial complex and create an entirely new chemical element, but still suffers through the inconvenient and mildly painful tribulation of numerous pin-prick blood tests a day.
Draper Laboratories, right down the street from Stark's alma mater, MIT, has a solution. A scientist at the lab has successfully demonstrated an implantable nanosensor that changes color as chemical concentrations fluctuate in the bloodstream.
Medgraph Inc. accuses Medtronic Inc. of violating one of its telemedicine patents with Medtronic's Carelink diabetes management system.
A relative bantam is stepping into the patent infringement ring with one of the industry's heavyweights.
Medgraph Inc., a Rochester, N.Y.-based telemedicine firm, sued Medtronic Inc. (NYSE:MDT), accusing the Minneapolis medical device monolith of patent infringement for its Carelink diabetes management system.
Echo Therapeutics Inc. is gearing up for a campaign to attract new investors next year, hiring investor relations consulting firm Hayden IR to develop and implement the campaign.
Echo Therapeutics Inc. (OTC:ECTE) is gearing up for a push to land new investors next year, which it expects to be "transformative," hiring a New York-based investor relations consulting firm to manage a "strategic investor relations campaign."
Hayden IR will develop and implement the Franklin, Mass.-based company's bid to attract more investors in 2010. Echo is developing needle-free drug delivery technologies, including a non-invasive, wireless glucose monitoring device and skin preparation system for transdermal drug delivery.
Franklin, Mass.-based device-maker heads to Ben Franklin's home turf to put the finishing touches on a $3.6 million fund-raising effort.
Echo Therapeutics Inc. (OTCBB:ECTE) wrapped up its latest fund-raising effort this week, tapping into the old-money network in and around the City of Brotherly Love.
The Franklin, Mass.-based company's needle-free Symphony tCGM Biosensor turned in a 97 percent accuracy rate in a clinical trial of patients with Type I and Type II diabetes.
Echo Therapeutics Inc. (ECTE) is touting preliminary results of a clinical trial of its Symphony tCGM Biosensor glucose monitor in patients with Type I and Type II diabetes.
The Franklin, Mass.-based glucose monitor maker sells about 2.4 million shares at $1.25 per share in a private placement.
Echo Therapeutics Inc. (ECTE) drummed up about $3 million in a private stock sale.
The Franklin, Mass.-based company, which is developing a non-invasive, wireless transdermal continuous glucose monitoring system, said it sold roughly 2.37 million share for $1.25 each, and issued about 2.2 million warrants with a $2.00 exercise price.